Overview

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the safety and effectiveness of Sintilimab Combined With Docetaxel in Non-driver Gene Mutation NSCLC patients who failed with double platinum-based chemotherapy
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Yongchang Zhang
Treatments:
Docetaxel
Criteria
Inclusion Criteria:

- Life expectancy exceeds 3 months

- The investigator confirmed at least one measurable lesion according to the RECIST 1.1
standard.

Exclusion Criteria:

- small cell lung cancer or small cell lung cancer

- Currently involved in interventional clinical research or treatment, or have received
other research drugs or used research equipment within 4 weeks prior to the first
dose;

- Previously received the following treatments: anti-PD-1, anti-PD-L1 or anti-PD-L2
drugs or drugs that stimulate or synergistically inhibit T cell receptors (eg, CTLA-4,
OX-40, CD137);